Pulmonary Tuberculosis Clinical Trial
Official title:
Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance in a Region With High Prevalence of the Disease: Randomized Clinical Trial
Brazil ranks 17th among the 22 countries responsible for 80% of tuberculosis (TB) cases in
the world. In 2010, the number of new cases of tuberculosis in Brazil was 71,930 and in 4972
RS. In 2010, Brazil had a disease incidence of 37.6 / 100,000 in 2011 fell to 36.0 /
100,000. The Rio Grande do Sul(RS)S showed an incidence rate of 46.1 / 100,000 in 2011. The
mortality rate was 2.4 / 100,000 population per year in Brazil and RS.
In Porto Alegre, the incidence rate of all clinical forms of tuberculosis has remained, in
the last six years, around 100/100.000 inhabitants per year, while the coefficient of
pulmonary tuberculosis remained on average 50/100.000 inhabitants to year. Thus, Porto
Alegre holds the 2nd place in Brazil among the capitals with the highest incidence of TB,
classifying the city as high risk 5th. Porto Alegre also has a co-infection TB / HIV from
35.3% one of the highest in the country.
The best strategy to prevent new cases of tuberculosis is to invest in early diagnosis and
effective treatment of existing cases of the disease. As the treatment of the disease
requires daily use of medications for an extended period of time (at least 6 months),
adherence becomes the main determinant of the rate of healing of disease.
There are several factors that contribute to poor adherence and treatment dropout:
alcoholism, illicit drug use, infection with human immunodeficiency virus (HIV Human
Immunodeficiency Virus), low education, unemployment, poor housing and prolonged the
treatment. The irregular treatment and neglect are the major obstacles to the control and
elimination of this disease.
Study in Porto Alegre pointed alcoholism, TB / HIV, the fact that the patient does not
reside with family and low education as predictors of dropout. The dropout rate in the
general population of patients with active tuberculosis was 10.7% (8.0% - 17.0%).
Abandonment occurred more often within the first three meses8.
In Porto Alegre, 32.5% of new TB cases are diagnosed in hospitals. Twenty percent of these
patients do not bind, after discharge, the Tuberculosis Control Program (TCP), ie, the
patient egress from the hospital does not reach the basic health unit (BHU) reference for
further monitoring and treatment, which is considered a serious flaw in the process control
of the disease.
Primary objective Test the impact on the tuberculosis cure rate of an intervention based on education and supervision from a distance in the post-discharge management of new cases diagnosed in hospital. ;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02736864 -
Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae
|
N/A | |
Not yet recruiting |
NCT04055441 -
A Study of Pattern of Presentation of Pulmonary Tuberculosis Patients Undergoing Treatment at Assiut University Hospital
|
||
Completed |
NCT02349841 -
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT01927159 -
Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT01691534 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
|
Phase 2 | |
Completed |
NCT00803322 -
Improving Community Based Tuberculosis Care in Ethiopia
|
Phase 4 | |
Completed |
NCT00834353 -
Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
|
N/A | |
Withdrawn |
NCT03277742 -
Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
|
N/A | |
Completed |
NCT00057434 -
Vitamin A Therapy for Tuberculosis
|
Phase 3 | |
Not yet recruiting |
NCT06192160 -
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
|
Phase 2 | |
Recruiting |
NCT06127641 -
Rehabilitation of People With Post-tuberculosis Lung Disease
|
N/A | |
Recruiting |
NCT06058299 -
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT04550832 -
PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
|
Phase 2 | |
Completed |
NCT02912832 -
Prospective Assessment of TBDx Feasibility
|
N/A | |
Completed |
NCT01215851 -
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)
|
Phase 2 | |
Recruiting |
NCT01503099 -
Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease
|
N/A | |
Completed |
NCT04608955 -
Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
|
Phase 2 | |
Recruiting |
NCT05046366 -
Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.
|
||
Completed |
NCT05896930 -
Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
|
Phase 2 | |
Completed |
NCT02279875 -
A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
|
Phase 2 |